A common variable immunodeficiency genetic test searches for inherited or newly occurring DNA variants that can cause a CVID-like immune disorder. It may examine a targeted immune-gene panel, the protein-coding exome, or the whole genome. Genes such as NFKB1, NFKB2, CTLA4, LRBA, ICOS, TNFRSF13B, and several B-cell signaling genes may be included, but no single gene explains most cases.
CVID remains primarily a clinical and laboratory diagnosis based on low immunoglobulin levels, impaired antibody responses, compatible symptoms, and exclusion of secondary causes. Genetic testing can refine that diagnosis, especially in children, people with severe immune dysregulation, affected relatives, unusual infections, or features that suggest a specific inborn error of immunity. A positive molecular result may change treatment and family testing. A negative result does not rule out CVID because many affected people have no currently identifiable single-gene cause.
- CVID genetic testing may identify a specific inborn error of immunity, but it is not required to diagnose every case of CVID.
- A positive pathogenic variant can clarify inheritance, guide family testing, and sometimes support targeted treatment.
- A negative panel does not exclude CVID; most cases remain genetically unexplained or involve complex causes.
- Testing usually uses blood, saliva, or a cheek swab and does not require fasting.
- Low IgG alone is not enough for diagnosis; vaccine responses, other immunoglobulins, symptoms, and secondary causes must also be assessed.
Table of Contents
- What a CVID Genetic Test Is
- Genes and Inheritance Patterns
- Who May Benefit From Genetic Testing
- Samples, Methods, and the Testing Process
- Understanding Positive, Negative, and Uncertain Results
- How a Molecular Diagnosis Can Change Care
- Limitations and Common Interpretation Mistakes
- Family Testing and Next Steps
What a CVID Genetic Test Is
A CVID genetic test looks for variants in genes that control antibody production, B-cell development, T-cell regulation, immune signaling, and tolerance. The test is intended to identify a molecular cause for a person whose clinical picture resembles common variable immunodeficiency or another predominantly antibody deficiency.
CVID is an umbrella diagnosis rather than one uniform genetic disease. People with CVID typically have markedly reduced IgG and reduced IgA, IgM, or both, along with poor production of specific antibodies. Many have recurrent sinus infections, ear infections, bronchitis, or pneumonia. Others first come to medical attention because of autoimmune cytopenias, enlarged lymph nodes or spleen, granulomatous inflammation, chronic diarrhea, inflammatory bowel disease-like symptoms, lung disease, or lymphoma.
The diagnosis usually requires more than a single low immunoglobulin result. Clinicians confirm persistent hypogammaglobulinemia, assess responses to vaccines or natural infections, review B- and T-cell subsets, and exclude other explanations. Secondary causes include protein loss, certain medications, blood cancers, nephrotic syndrome, intestinal disease, and other acquired conditions. Age also matters because young children may have transient or evolving antibody deficiencies.
Genetic testing does not replace this immune evaluation. Instead, it can reclassify a CVID phenotype as a specific inborn error of immunity. That distinction may matter because two people with similar IgG levels can have very different risks, complications, inheritance patterns, and treatment options.
A broad genetic diagnostic test may produce a definitive molecular diagnosis, an uncertain result, or no finding. The laboratory report should be interpreted in the context of the person’s immune phenotype rather than treated as an isolated answer.
Genes and Inheritance Patterns
Dozens of genes can produce CVID-like features, but the strength of evidence and clinical implications vary. Some variants directly cause a monogenic immune disorder. Others, especially certain variants in TNFRSF13B, may increase susceptibility or modify disease without being sufficient on their own.
Frequently discussed genes include:
| Gene or pathway | Possible clinical clues | Why the result may matter |
|---|---|---|
| NFKB1 | Antibody deficiency, recurrent infections, autoimmunity, variable age at onset | Can establish an autosomal dominant disorder with variable penetrance |
| NFKB2 | Antibody deficiency, endocrine abnormalities, alopecia, viral infections | May prompt endocrine and broader immune surveillance |
| CTLA4 | Autoimmune cytopenias, enteropathy, lymphoproliferation, organ infiltration | May support targeted immunomodulatory treatment in selected cases |
| LRBA | Early-onset autoimmunity, chronic diarrhea, low immunoglobulins, recurrent infections | Can influence treatment intensity and transplant discussions |
| ICOS | Antibody deficiency, recurrent bacterial infections, low switched memory B cells | Can define a recessive immunodeficiency |
| TNFRSF13B | CVID or selective IgA deficiency phenotype | Interpretation is complex because some variants occur in healthy people |
| CD19, CD81, CR2, MS4A1 | Impaired antibody responses with abnormal B-cell signaling | May identify a defined B-cell pathway defect |
| PIK3CD, PIK3R1 | Recurrent respiratory and herpesvirus infections, lymphoproliferation, senescent T cells | Can indicate activated PI3K-delta syndrome and targeted therapy options |
Inheritance may be autosomal dominant, autosomal recessive, X-linked, or de novo. In an autosomal dominant disorder, one pathogenic copy can be sufficient, but not every carrier has the same symptoms. Reduced penetrance and variable expressivity are common. A parent may appear healthy or have only recurrent sinus infections, while a child has severe autoimmunity or lung disease.
Autosomal recessive conditions generally require pathogenic variants in both copies of a gene. Parents usually carry one variant and may have no symptoms. X-linked disorders often affect males more severely, although female carriers can sometimes show immune abnormalities because of X-chromosome inactivation.
A de novo variant arises in the egg, sperm, or early embryo and is not found in either parent’s blood. It can explain a severe case without a family history. Confirming whether a result is inherited or de novo often requires parental testing.
CVID can also be polygenic or multifactorial. In those cases, many common variants and regulatory effects may combine with infections, epigenetic changes, and other influences. Current clinical testing is much better at identifying rare, high-impact variants than explaining complex susceptibility.
Who May Benefit From Genetic Testing
Genetic testing is most likely to provide useful information when the clinical pattern suggests a monogenic disorder. Testing may be considered for any person with CVID, but the expected diagnostic yield is higher in selected groups.
Features that strengthen the case for testing include:
- Onset in childhood, especially infancy or early school age
- Multiple affected relatives or parental consanguinity
- Severe, persistent, unusual, or opportunistic infections
- Recurrent herpesvirus, fungal, mycobacterial, or vaccine-strain infections
- Autoimmune cytopenias, enteropathy, arthritis, endocrinopathy, or multiple autoimmune organs
- Enlarged spleen, persistent lymphadenopathy, granulomas, or benign lymphoid infiltration
- Interstitial or granulomatous lung disease
- Marked abnormalities in T-cell, B-cell, or natural killer cell numbers or function
- Developmental differences, dysmorphic features, neurologic findings, or growth problems
- Malignancy at an unusually young age
- A phenotype that does not fit standard CVID criteria cleanly
Adults with apparently typical infection-predominant CVID can also have a monogenic cause, so age alone should not prevent testing. However, the chance of a definitive result is generally lower when onset is late, there is no family history, and the phenotype is limited to common respiratory infections.
Testing can be especially valuable before major treatment decisions. A molecular diagnosis may influence whether clinicians use targeted immune therapy, avoid a particular drug, screen for a complication, or consider hematopoietic stem cell transplantation. It can also prevent diagnostic drift, in which a person accumulates several labels without one explanation tying them together.
Genetic counseling before testing helps define expectations. The discussion should cover the possibility of a negative result, a VUS, incidental findings, unexpected family relationships, and results relevant to relatives. For broad testing, a clinician may choose a single-gene genetic test, a multigene panel, exome sequencing, or genome sequencing based on the phenotype and prior workup.
Samples, Methods, and the Testing Process
Testing usually begins with a blood sample. Saliva or a cheek swab may be acceptable for some assays, but blood is often preferred in immunology clinics because it provides reliable DNA and can be collected with immune-function studies. Fasting is not required, and immunoglobulin replacement does not change a person’s germline DNA.
The major test options are:
Targeted single-gene testing
This approach is appropriate when the phenotype strongly points to one condition or when a known familial variant is present. It offers focused analysis and reduces the chance of unrelated findings, but it can miss an unexpected diagnosis.
Inborn error of immunity panel
Panels analyze dozens to hundreds of genes associated with primary immunodeficiency and immune dysregulation. They often include sequencing plus deletion and duplication analysis. Panel content differs among laboratories, so the ordering clinician should confirm that relevant genes and variant types are covered.
Exome sequencing
Exome sequencing reads most protein-coding regions. It is useful when the phenotype is broad or panel testing is negative. Trio testing of the affected person and both biological parents can improve interpretation by identifying de novo variants, determining phase, and filtering inherited benign variation.
Genome sequencing
Genome sequencing covers coding and noncoding DNA more broadly and may detect structural variants that exome testing misses. It still does not identify every disease mechanism, and interpretation of noncoding variation remains limited.
RNA, protein, or functional testing
Some DNA findings require confirmation that a variant changes RNA splicing, protein expression, or cell function. Flow cytometry, immunoblotting, proliferation assays, cytokine studies, and other functional tests may help establish pathogenicity. These studies are often available only through specialized laboratories.
Turnaround time varies from a few weeks to several months. Before ordering, ask whether the laboratory reports secondary findings, whether copy-number and mitochondrial variants are included, and whether data can be reanalyzed later. A genetic panel test is only as comprehensive as its current gene list and validated technical coverage.
The clinician should send detailed phenotype information. Terms such as “recurrent infection” are less useful than specific details: age at first pneumonia, organisms identified, vaccine responses, IgG/IgA/IgM levels, lymphocyte subsets, autoimmune diagnoses, imaging findings, and affected relatives. Better phenotyping can improve variant prioritization and interpretation.
Understanding Positive, Negative, and Uncertain Results
A CVID genetic report usually classifies variants as pathogenic, likely pathogenic, uncertain significance, likely benign, or benign. The classification describes the evidence for the variant, not the severity of the person’s symptoms.
Pathogenic or likely pathogenic result
A pathogenic or likely pathogenic variant may establish a molecular diagnosis when the gene, inheritance pattern, and clinical features align. For a dominant condition, one altered copy may be enough. For a recessive condition, two disease-causing variants generally must be identified on opposite copies of the gene.
The report may state that the result is “consistent with,” “diagnostic of,” or “supports” a particular inborn error of immunity. The care team should still verify that the phenotype fits and may order confirmatory functional testing. In some genes, a variant can have different effects depending on its location or mechanism.
Susceptibility or risk variant
Not every reported variant is fully causative. TNFRSF13B variants illustrate this problem. Certain changes are enriched among people with CVID or IgA deficiency, but some are also found in unaffected relatives and the general population. A single susceptibility variant may contribute to disease without explaining it completely. The report’s language and population frequency matter.
Variant of uncertain significance
A VUS means evidence is insufficient to call the variant harmful or harmless. It should not be used alone to diagnose a condition, test healthy relatives for predictive purposes, or justify irreversible treatment. Segregation studies may help if multiple affected and unaffected relatives are available, but they do not always resolve uncertainty.
A VUS can later be reclassified. Families should keep contact information current with the ordering clinic and ask whether the laboratory offers automatic updates or periodic reanalysis. The principles are the same as those described for a variant of uncertain significance in other genetic disorders.
Negative result
A negative result means the test did not identify a reportable variant that explains the phenotype. It does not disprove CVID. Possible reasons include:
- The cause is polygenic or multifactorial.
- The responsible gene has not yet been linked to human disease.
- The variant lies in a region the test did not cover well.
- The change is structural, regulatory, mosaic, epigenetic, or otherwise difficult to detect.
- A detected variant could not yet be interpreted as pathogenic.
- The immune abnormality is acquired rather than inherited.
The clinical diagnosis and treatment plan may remain unchanged after a negative test. Reanalysis in one to three years, or sooner if the phenotype changes, can identify newly recognized genes or reclassified variants.
How a Molecular Diagnosis Can Change Care
A molecular diagnosis can do more than attach a gene name to CVID. It may reveal a different natural history, direct surveillance, and identify treatments that target the affected pathway.
For example, CTLA4 haploinsufficiency and LRBA deficiency can produce recurrent infections, low immunoglobulins, autoimmune cytopenias, enteropathy, and lymphocytic organ infiltration. Recognizing the pathway may support use of abatacept in selected patients under specialist care. Activated PI3K-delta syndrome caused by PIK3CD or PIK3R1 variants may lead to consideration of pathway-specific therapy and closer monitoring for herpesvirus infection, lymphoproliferation, and malignancy. NFKB2-related disease may prompt endocrine evaluation because pituitary or adrenal abnormalities can occur.
A result may also alter decisions about stem cell transplantation. Transplant is not routine treatment for typical CVID, but it may be considered for life-threatening immune dysregulation, severe combined immune defects, refractory complications, or specific monogenic conditions. Molecular information can help estimate whether the underlying defect is corrected by donor-derived blood and immune cells.
Other potential changes include:
- Screening for organ-specific complications associated with the gene
- Adjusting the frequency of lung imaging or pulmonary testing
- Monitoring for lymphoma or other malignancy when justified
- Avoiding live vaccines in conditions with significant T-cell dysfunction
- Selecting immunosuppressive drugs more carefully
- Testing a potential related stem cell donor for the familial variant
- Clarifying whether immunoglobulin replacement is likely to remain long term
- Connecting the family with condition-specific trials or registries
Not every positive result changes therapy. Some findings primarily clarify inheritance or prognosis. Treatment still depends on actual infections, immune function, organ involvement, and response to care. A gene result should not prompt off-label targeted therapy without an immunologist who understands the relevant evidence and risks.
Immunoglobulin replacement remains the foundation for many people with clinically significant antibody failure. Antibiotics, vaccination strategies, airway clearance, pulmonary care, treatment of autoimmunity, and cancer surveillance may still be needed whether or not a molecular cause is found.
Limitations and Common Interpretation Mistakes
The diagnostic yield of genetic testing varies widely because study populations and testing methods differ. Yield tends to be higher in children, consanguineous families, severe immune dysregulation, and cohorts selected for unusual features. A quoted percentage from one study should not be applied automatically to every person with CVID.
Technical limits also differ. Some panels sequence only coding exons and nearby splice sites. Others include copy-number analysis, selected intronic regions, mitochondrial DNA, and difficult genes. A “negative 400-gene panel” may sound comprehensive but still miss a promoter variant, balanced rearrangement, low-level mosaic variant, repeat expansion, or newly discovered gene.
Common mistakes include:
- Assuming one low IgG result proves CVID. Levels should be repeated and secondary causes assessed.
- Using a VUS as a confirmed diagnosis. Uncertain variants require restraint and periodic review.
- Calling every TNFRSF13B variant causative. Some variants act as risk factors or have incomplete penetrance.
- Ignoring phenotype mismatch. A pathogenic variant in a gene unrelated to the person’s findings may be incidental or require careful reassessment.
- Testing relatives before confirming the proband’s result. Family testing is most informative after the exact variant and inheritance model are established.
- Assuming a negative result means the immune system is normal. Immune function is measured with immunology tests, not inferred from a negative DNA panel.
- Stopping treatment after an inconclusive result. Clinical need for immunoglobulin or infection prevention does not depend on finding a gene.
Somatic mosaicism is another consideration. A variant present in only a fraction of cells may be missed or appear at low read depth. Some acquired blood-cell clones can also complicate interpretation, especially in older adults or people with hematologic disease. The laboratory may recommend testing a second tissue in unusual cases.
Data interpretation evolves rapidly. A result that was negative five years ago may warrant reanalysis using updated gene-disease knowledge. Reanalysis is often more efficient than immediately repeating sample collection, provided the laboratory retained high-quality data.
Family Testing and Next Steps
After receiving a result, request a visit with the ordering immunologist and, when available, a genetic counselor or clinical geneticist. Bring the full report, immune laboratory results, medication list, infection history, and a three-generation family history.
For a pathogenic or likely pathogenic variant, the next steps usually include:
- Confirm that the gene and inheritance pattern fit the clinical picture.
- Decide whether functional confirmation is needed.
- Review gene-specific treatment and surveillance recommendations.
- Test biological parents to determine whether the variant is inherited or de novo.
- Offer targeted testing to relatives who could have inherited the variant.
- Discuss reproductive implications and available options.
- Reassess any related donor before stem cell collection.
Predictive testing of healthy children requires special care. It is generally most appropriate when childhood surveillance, infection precautions, or treatment would change. For adult-onset or variably penetrant conditions, counseling should address uncertainty and the emotional effects of knowing carrier status.
Reproductive risks depend on inheritance. A person with a dominant pathogenic variant may have a 50% chance of passing it to each child, although disease expression can vary. When both parents carry variants in the same recessive gene, each pregnancy generally has a 25% chance of an affected child. X-linked risks depend on the sex chromosomes of the parent and child. De novo variants can still carry a recurrence risk because of possible germline mosaicism.
Options may include natural conception with prenatal diagnosis, in vitro fertilization with preimplantation genetic testing, donor eggs or sperm, adoption, or choosing not to pursue testing. These are personal decisions, and counseling should present them without pressure.
For a negative result, continue care based on the established immune phenotype. Ask whether the test included deletion/duplication analysis, whether exome or genome sequencing is appropriate, and when reanalysis should occur. New symptoms—such as autoimmune disease, unexplained lymph node enlargement, progressive lung problems, or unusual infections—may provide clues that justify renewed analysis.
CVID genetic testing is most valuable when it is paired with careful immunology. DNA can reveal why the immune system is failing in some families, but the absence of a molecular answer does not diminish the reality of measured antibody deficiency or the need for treatment.
References
- Exploring Monogenic, Polygenic, and Epigenetic Models of Common Variable Immunodeficiency 2025 (Review)
- Monogenic Common Variable Immunodeficiency (Mo-CVID) Score for Optimizing the Genetic Diagnosis in Pediatric CVID Cohort 2025
- Genetics and clinical phenotypes in common variable immunodeficiency 2024 (Review)
- Immunogenetic Landscape in Pediatric Common Variable Immunodeficiency 2024 (Review)
- The Rapidly Expanding Genetic Spectrum of Common Variable Immunodeficiency-Like Disorders 2023 (Review)
- Monogenic forms of common variable immunodeficiency and implications on target therapeutic approaches 2023 (Review)
Disclaimer
CVID diagnosis and treatment require specialist evaluation of immunoglobulins, antibody function, infections, and secondary causes. Genetic results should not be used alone to start, stop, or alter immunoglobulin replacement or immunosuppressive therapy. Discuss pathogenic variants, uncertain findings, and family testing with a clinical immunologist and genetics professional.
